Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 4/20 | 1.00 |
| ▸ | PPARD | Q03181 | 4/20 | 1.00 |
| ▸ | PPARA | Q07869 | 4/20 | 1.00 |
| ▸ | NPC1 | O15118 | 7/20 | 0.69 |
| ▸ | RAB9A | P51151 | 7/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.69 |
| ▸ | MAPT | P10636 | 7/20 | 0.69 |
| ▸ | LMNA | P02545 | 2/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.68 |
| ▸ | HPGD | P15428 | 5/20 | 0.68 |
| ▸ | TP53 | P04637 | 4/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.68 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.68 |
| ▸ | MAOA | P21397 | 2/20 | 0.68 |
| ▸ | MAOB | P27338 | 2/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3950586 | 0.92 | PPARG (0.86) | PPARGPPARDPPARANPC1RAB9A | |
| SCHEMBL10562034 | 0.86 | PPARG (0.75) | PPARGPPARDPPARANPC1RAB9A | |
| SCHEMBL13904589 | 0.85 | PPARG (0.73) | PPARGPPARDPPARANPC1RAB9A | |
| SCHEMBL31134896 | 0.84 | PPARG (0.73) | PPARGPPARDPPARANPC1RAB9A | |
| SCHEMBL13904569 | 0.84 | PPARG (0.72) | PPARGPPARDPPARANPC1RAB9A | |
| SCHEMBL4191666 | 0.83 | PPARG (0.70) | PPARGPPARDPPARANPC1RAB9A | |
| SCHEMBL13267886 | 0.83 | PPARG (0.70) | PPARGPPARDPPARANPC1RAB9A | |
| SCHEMBL7760763 | 0.83 | PPARG (0.70) | PPARGPPARDPPARANPC1RAB9A | |
| SCHEMBL29887469 | 0.83 | PPARG (0.70) | PPARGPPARDPPARANPC1RAB9A | |
| Daidzein SCHEMBL21114371 | 0.82 | KDM4E (1.00) | PPARGPPARDPPARANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 265 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250051551-A1 | IMPROVED POLYMER COMPOSITES | WARNER BABCOCK INSTITUTE FOR GREEN CHEMISTRY, LLC (US) | 2025-02-13 | — | — | US | claimed |
| US-20240315965-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2024-09-26 | — | — | US | claimed |
| US-20230089351-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2023-03-23 | — | — | US | claimed |
| WO-2022182523-A1 | COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2022-09-01 | — | — | WO | claimed |
| WO-2022182527-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2022-09-01 | — | — | WO | claimed |
| CN-114642695-A | Big data traditional Chinese medicine composition for regulating and controlling prostate cancer | 华子昂 | 2022-06-21 | — | — | CN | claimed |
| WO-2021158573-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2021-08-12 | — | — | WO | claimed |
| WO-2021158575-A1 | COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2021-08-12 | — | — | WO | claimed |
| WO-2021042001-A1 | COMPOSITIONS AND METHODS RELATED TO DISSOLVED OXIDES | Natural Extraction Systems, LLC (US) | 2021-03-04 | — | — | WO | claimed |
| US-20200405797-A1 | TRANSMUCOSAL DELIVERY DEVICE AND METHOD OF MANUFACTURING SAME | NANOSTRIPS, INC. (US) | 2020-12-31 | — | — | US | claimed |
| US-20260048025-A1 | COMPOSITIONS AND METHODS RELATED TO DISSOLVED OXIDES | NATURAL EXTRACTION SYS LLC (US) | 2026-02-19 | — | — | US | disclosed |
| EP-4190172-B1 | SWEETENER COMPOSITION COMPRISING STEVIOL GLYCOSIDE SWEETENERS WITH IMPROVED FLAVOR PROFILES | COCA COLA CO (US) | 2025-11-26 | — | — | EP | disclosed |
| US-12409152-B2 | Compositions and methods related to dissolved oxides | Natural Extraction Systems, LLC (US) | 2025-09-09 | — | — | US | disclosed |
| US-20250161394-A1 | Compositions Comprising Kavalactones | NATURAL EXTRACTION SYS LLC (US) | 2025-05-22 | — | — | US | disclosed |
| WO-2025049925-A2 | LIPIDOID COMPOUNDS AND RELATED COMPOSITIONS AND USES | POSEIDA THERAPEUTICS, INC. (US) | 2025-03-06 | — | — | WO | disclosed |
| WO-1999049862-A1 | ISOFLAVONES FOR TREATING GIARDIASIS AND MALARIA | THE UNIVERSITY OF MISSISSIPPI (US) | 1999-10-07 | — | — | WO | disclosed |
| EP-0742012-A2 | Pharmaceutical composition containing substance inhibiting HSP47 production | Kureha Chemical Industry Co., Ltd. (JP) | 1996-11-13 | — | — | EP | disclosed |
| EP-0101639-B1 | PROCESS FOR ISOLATING SAPONINS AND FLAVONOIDS FROM LEGUMINOUS PLANTS | TOKIWA KANPO PHARMACEUTICAL CO., LTD. (JP) | 1988-04-27 | — | — | EP | disclosed |
| EP-0101639-A2 | Process for isolating saponins and flavonoids from leguminous plants | TOKIWA KANPO PHARMACEUTICAL CO., LTD. (JP) | 1984-02-29 | — | — | EP | disclosed |
| US-4428876-A | Process for isolating saponins and flavonoids from leguminous plants | TOKIWA KANPO PHARMACEUTICAL CO., LTD. (JP) | 1984-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230089351-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | FABP2, FABP4, GUSB | PPARG 319/4885PPARD 1368/4885PPARA 433/4885 |
| US-12409152-B2 | Compositions and methods related to dissolved oxides | PRKG2, PRKG1, CIT | PPARG 3026/4885PPARD 4060/4885PPARA 3956/4885 |
| US-20260048025-A1 | COMPOSITIONS AND METHODS RELATED TO DISSOLVED OXIDES | SCO2, CNR2, CNR1 | PPARG 513/4885PPARD 1062/4885PPARA 930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.